Loading…
Immune-Cell-Based Therapy for COVID-19: Current Status
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy t...
Saved in:
| Published in: | Viruses 2023-10, Vol.15 (11), p.2148 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c441t-ec2c44981c62c7f29ba4b9bdbcf00bc1f4d0033271f5b8dd990612784b153eae3 |
| container_end_page | |
| container_issue | 11 |
| container_start_page | 2148 |
| container_title | Viruses |
| container_volume | 15 |
| creator | Wang, Yiyuan Liang, Qinghe Chen, Fengsheng Zheng, Jiehuang Chen, Yan Chen, Ziye Li, Ruopeng Li, Xiaojuan |
| description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment. |
| doi_str_mv | 10.3390/v15112148 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e6ccbc0c689240c3989fda6f568019b3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A774377760</galeid><doaj_id>oai_doaj_org_article_e6ccbc0c689240c3989fda6f568019b3</doaj_id><sourcerecordid>A774377760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-ec2c44981c62c7f29ba4b9bdbcf00bc1f4d0033271f5b8dd990612784b153eae3</originalsourceid><addsrcrecordid>eNptkUlvFDEQhS1ERELgwB9ALXGBQ4fy0l64Jc2SkSLlQOBqeQ09mm4PdjdS_j1OJgwhQnWoUumrZz89hF5hOKFUwftfuMOYYCafoCOslGqZwt3TB_Mhel7KGoBzBeIZOqQSoJOEHyG-GsdlCm0fNpv2zJTgm6sfIZvtTRNTbvrL76uPLVYfmn7JOUxz83U281JeoINoNiW8vO_H6NvnT1f9eXtx-WXVn160jjE8t8GROiiJHSdORKKsYVZZb10EsA5H5gEoJQLHzkrvlQKOiZDM4o4GE-gxWu10fTJrvc3DaPKNTmbQd4uUr7XJ8-A2QQfunHXguFSEgaNKqugNjx2XgJWlVevtTmub088llFmPQ3HVt5lCWoomUlHJGCOiom8eoeu05Kk6vaNoB0TKv9S1qe8PU0xzNu5WVJ8KwagQgkOlTv5D1fJhHFyaQhzq_p-Dd7sDl1MpOcS9bwz6Nm-9z7uyr-8_utgx-D35J2D6G6lNn1I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2893350288</pqid></control><display><type>article</type><title>Immune-Cell-Based Therapy for COVID-19: Current Status</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Wang, Yiyuan ; Liang, Qinghe ; Chen, Fengsheng ; Zheng, Jiehuang ; Chen, Yan ; Chen, Ziye ; Li, Ruopeng ; Li, Xiaojuan</creator><creatorcontrib>Wang, Yiyuan ; Liang, Qinghe ; Chen, Fengsheng ; Zheng, Jiehuang ; Chen, Yan ; Chen, Ziye ; Li, Ruopeng ; Li, Xiaojuan</creatorcontrib><description>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.</description><identifier>ISSN: 1999-4915</identifier><identifier>EISSN: 1999-4915</identifier><identifier>DOI: 10.3390/v15112148</identifier><identifier>PMID: 38005826</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Bone marrow ; Cell therapy ; Cell- and Tissue-Based Therapy ; Cells ; Clinical trials ; Coronaviruses ; COVID-19 ; COVID-19 - therapy ; COVID-19 Drug Treatment ; Cytokines ; Cytotoxicity ; Fatalities ; Health aspects ; Humans ; Immune response ; Immunity, Innate ; Immunotherapy ; Infections ; Infectious diseases ; Inflammation ; Lymphocytes ; Medical research ; Medicine, Experimental ; Pathogenesis ; Proteins ; Respiratory distress syndrome ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Thymus gland ; Umbilical cord ; Viral infections</subject><ispartof>Viruses, 2023-10, Vol.15 (11), p.2148</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c441t-ec2c44981c62c7f29ba4b9bdbcf00bc1f4d0033271f5b8dd990612784b153eae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2893350288/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2893350288?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,38516,43895,44590,74284,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38005826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yiyuan</creatorcontrib><creatorcontrib>Liang, Qinghe</creatorcontrib><creatorcontrib>Chen, Fengsheng</creatorcontrib><creatorcontrib>Zheng, Jiehuang</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Chen, Ziye</creatorcontrib><creatorcontrib>Li, Ruopeng</creatorcontrib><creatorcontrib>Li, Xiaojuan</creatorcontrib><title>Immune-Cell-Based Therapy for COVID-19: Current Status</title><title>Viruses</title><addtitle>Viruses</addtitle><description>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.</description><subject>Antigens</subject><subject>Bone marrow</subject><subject>Cell therapy</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Cells</subject><subject>Clinical trials</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - therapy</subject><subject>COVID-19 Drug Treatment</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Fatalities</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunity, Innate</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Inflammation</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Pathogenesis</subject><subject>Proteins</subject><subject>Respiratory distress syndrome</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thymus gland</subject><subject>Umbilical cord</subject><subject>Viral infections</subject><issn>1999-4915</issn><issn>1999-4915</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkUlvFDEQhS1ERELgwB9ALXGBQ4fy0l64Jc2SkSLlQOBqeQ09mm4PdjdS_j1OJgwhQnWoUumrZz89hF5hOKFUwftfuMOYYCafoCOslGqZwt3TB_Mhel7KGoBzBeIZOqQSoJOEHyG-GsdlCm0fNpv2zJTgm6sfIZvtTRNTbvrL76uPLVYfmn7JOUxz83U281JeoINoNiW8vO_H6NvnT1f9eXtx-WXVn160jjE8t8GROiiJHSdORKKsYVZZb10EsA5H5gEoJQLHzkrvlQKOiZDM4o4GE-gxWu10fTJrvc3DaPKNTmbQd4uUr7XJ8-A2QQfunHXguFSEgaNKqugNjx2XgJWlVevtTmub088llFmPQ3HVt5lCWoomUlHJGCOiom8eoeu05Kk6vaNoB0TKv9S1qe8PU0xzNu5WVJ8KwagQgkOlTv5D1fJhHFyaQhzq_p-Dd7sDl1MpOcS9bwz6Nm-9z7uyr-8_utgx-D35J2D6G6lNn1I</recordid><startdate>20231025</startdate><enddate>20231025</enddate><creator>Wang, Yiyuan</creator><creator>Liang, Qinghe</creator><creator>Chen, Fengsheng</creator><creator>Zheng, Jiehuang</creator><creator>Chen, Yan</creator><creator>Chen, Ziye</creator><creator>Li, Ruopeng</creator><creator>Li, Xiaojuan</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20231025</creationdate><title>Immune-Cell-Based Therapy for COVID-19: Current Status</title><author>Wang, Yiyuan ; Liang, Qinghe ; Chen, Fengsheng ; Zheng, Jiehuang ; Chen, Yan ; Chen, Ziye ; Li, Ruopeng ; Li, Xiaojuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-ec2c44981c62c7f29ba4b9bdbcf00bc1f4d0033271f5b8dd990612784b153eae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antigens</topic><topic>Bone marrow</topic><topic>Cell therapy</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Cells</topic><topic>Clinical trials</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - therapy</topic><topic>COVID-19 Drug Treatment</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Fatalities</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunity, Innate</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Inflammation</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Pathogenesis</topic><topic>Proteins</topic><topic>Respiratory distress syndrome</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thymus gland</topic><topic>Umbilical cord</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yiyuan</creatorcontrib><creatorcontrib>Liang, Qinghe</creatorcontrib><creatorcontrib>Chen, Fengsheng</creatorcontrib><creatorcontrib>Zheng, Jiehuang</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Chen, Ziye</creatorcontrib><creatorcontrib>Li, Ruopeng</creatorcontrib><creatorcontrib>Li, Xiaojuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Viruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yiyuan</au><au>Liang, Qinghe</au><au>Chen, Fengsheng</au><au>Zheng, Jiehuang</au><au>Chen, Yan</au><au>Chen, Ziye</au><au>Li, Ruopeng</au><au>Li, Xiaojuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune-Cell-Based Therapy for COVID-19: Current Status</atitle><jtitle>Viruses</jtitle><addtitle>Viruses</addtitle><date>2023-10-25</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>2148</spage><pages>2148-</pages><issn>1999-4915</issn><eissn>1999-4915</eissn><abstract>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38005826</pmid><doi>10.3390/v15112148</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1999-4915 |
| ispartof | Viruses, 2023-10, Vol.15 (11), p.2148 |
| issn | 1999-4915 1999-4915 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_e6ccbc0c689240c3989fda6f568019b3 |
| source | Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
| subjects | Antigens Bone marrow Cell therapy Cell- and Tissue-Based Therapy Cells Clinical trials Coronaviruses COVID-19 COVID-19 - therapy COVID-19 Drug Treatment Cytokines Cytotoxicity Fatalities Health aspects Humans Immune response Immunity, Innate Immunotherapy Infections Infectious diseases Inflammation Lymphocytes Medical research Medicine, Experimental Pathogenesis Proteins Respiratory distress syndrome SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Thymus gland Umbilical cord Viral infections |
| title | Immune-Cell-Based Therapy for COVID-19: Current Status |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A19%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune-Cell-Based%20Therapy%20for%20COVID-19:%20Current%20Status&rft.jtitle=Viruses&rft.au=Wang,%20Yiyuan&rft.date=2023-10-25&rft.volume=15&rft.issue=11&rft.spage=2148&rft.pages=2148-&rft.issn=1999-4915&rft.eissn=1999-4915&rft_id=info:doi/10.3390/v15112148&rft_dat=%3Cgale_doaj_%3EA774377760%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c441t-ec2c44981c62c7f29ba4b9bdbcf00bc1f4d0033271f5b8dd990612784b153eae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2893350288&rft_id=info:pmid/38005826&rft_galeid=A774377760&rfr_iscdi=true |